Elutia Sells SimpliDerm for Up to $11M, Bolsters Cash Ahead of NXT-41x Launch
ELUT sits 87% above its 52-week low of $0.5 on elevated volume (6.3× avg).
Summary
Elutia signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics for up to $11 million — $8 million cash at closing plus up to $3 million in milestone payments over 18 months. The deal completes a previously announced strategic review and provides non-dilutive capital that strengthens the balance sheet ahead of the planned 2027 commercial launch of NXT-41x, its antibiotic-eluting biomatrix for breast reconstruction. With a market cap around $42 million and a recent history of widening losses and cash burn, the cash infusion is material and reduces near-term financing risk. The transaction also sharpens the company's focus on its lead pipeline asset in a $1.5 billion market. Closing is expected in the second half of 2026, subject to customary conditions.
At the time of this announcement, ELUT was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42M. The 52-week trading range was $0.50 to $2.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.